Analyst Conference Summaries

Biotechnology Investor Aids

Aprea Therapeutics
APRE

conference date: May 6, 2021 (press release only)

Aprea Therapeutics Cancer Therapy Platform Is Promising [July 21, 2020 at Seeking Alpha]

2021
Aprea
Therapeutics
Q1 2021 release
     
May 6, 2021      
2020
Aprea
Therapeutics
Q1 2020 release
Aprea
Therapeutics
Q2 2020 release
Aprea
Therapeutics
Q3 2020 release
Aprea
Therapeutics
Q4 2020 release
May 15, 2020 Aug. 11, 2020 Nov. 5, 2020 March 16, 2021

Aprea Therapeutics (APRE) is a clinical-stage biotechnology company specializing in therapies for cancers with TP53 mutations.

Aprea Therapeutics web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 BMY
 CLDX
 EPZM
 GILD
 GLYC
 ILMN
 INO
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLRN
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2021 William P. Meyers